Genetesis

Assessing Microvascular Disease – Beyond the Obvious Not all heart disease involves large vessel blockages. Microvascular disease affects the tiny vessels that supply your heart, often causing symptoms like chest pain. ?? At PICC, we go beyond traditional tests with specialized assessments to detect and treat microvascular issues early. We are involved in clinical research to bring tomorrow’s technology to you TODAY. Your heart health is in the details. #MicrovascularHealth #AdvancedCardiology #PICCIntervention #CardioFlux #CardioMagnetography #MICRO2.0 Genetesis Peeyush Shrivastava Robert Takla, MD, MBA, FACEP

Excited to announce the launch of the CardioFlux Membership program, now being offered directly out of our flagship imaging space here in Mason, Ohio. What we now call the CardioFlux Imaging Institute began as a small R&D space that has since transformed into an independent imaging center, allowing us to provide patients, physicians, and scientists in the local Cincinnati community with direct access to MCG technology. With the release of the CardioFlux Membership program, almost anybody living in and around Cincinnati now has the opportunity to regularly measure their myocardial fitness (i.e. the health of their heart muscle). The membership experience centers around regular scans with our CardioFlux MCG technology and has been designed to be the easiest, fastest, and safest way to repeatedly measure your underlying heart health. It's time to begin measuring our hearts the same way we measure simple things like how much we eat and what we weigh. Want to learn how a CardioFlux Membership can give you the ability to track changes in your heart you expect to see and catch the changes you weren't expecting? Learn more at cardioflux.com.

Check out the latest CV business white paper on #magnetocardiography! Discover how this innovative imaging modality is revolutionizing the diagnosis & treatment of ischemia. Genetesis LEARN MORE: https://hubs.li/Q02Y8C5n0

Spooktacular times at our annual Halloween costume contest!??? ?? Who do you think deserves the best-dressed title? Let us know in the comments!

We are thrilled to announce that Health Canada has officially approved CardioFlux MCG for the diagnosis of myocardial ischemia! ?? “This is our first foray beyond the US,” says Genetesis CEO, Peeyush Shrivastava, “and we’re excited to partner with physicians in Canada to improve both patient outcomes AND patient experience.” This milestone marks the first approval of an MCG device in Canadian regulatory history. Read the full press release here. #MICRO #CardioFluxMCG #microvascular #MAGNETO #CMD #myocardialischemia #INOCA #healthcanada

A note of congratulations to?PI Dr. Abhiram Prasad, Dr. Claire Raphael,?and the rest of the MICRO2 study team at Mayo Clinic on enrolling their first MICRO2 patient! With this latest installation of CardioFlux MCG at Mayo Clinic, our team is proud to share that our entire extended network of MICRO2 enrolling sites is fully activated and actively enrolling. Early evidence suggests that MCG may have a unique ability to help physicians diagnose CMD instantly and non-invasively, something that is not always true under the current standard of care. MICRO2 has been designed to test whether or not this hypothesis is true, with an eye on a potential De Novo application to the FDA next year. In conducting MICRO2, our team has been incredibly fortunate to partner with many of cardiology's foremost leaders in CMD research and care. Mayo Clinic is certainly no exception to that rule! Welcome aboard to?Drs. Prasad and Raphael?and the rest of their supporting team as we explore this new opportunity to make a significant dent into the problem of CMD. #MICRO2 #CardioFluxMCG #microvascular #CMD #myocardialischemia #INOCA

Congratulations to?PI Dr. Ankitkumar Patel, and his colleagues at Mountainside Medical Center, including?Valerie Allusson, Valarie McPherson, Joshua Jerome, Taneya Williams-Lewis, Alyssa A. Stolarik, Eugenio Hernandez, Stephanie Fabian, and Tim O'Brien,?on the enrollment of their facility's first patient in MICRO2! Despite extensive research across many years, the importance of coronary microvascular dysfunction (CMD) continues to be underrecognized and underappreciated in the current standard of care, all of this despite the fact that CMD has been correlated with a significantly increased risk of major adverse cardiac events (MACE) as well as overall mortality. Our team's hope is that an easier, faster, more accessible diagnostic option for CMD might change this trend and drive awareness around the importance of proper functional interrogation of a patient's potential ischemia. We're looking forward to continuing to collaborate with Dr. Patel and his team as we continue making progress on MICRO2! #MICRO2 #CardioFluxMCG #microvascular #CMD #myocardialischemia #INOCA

Congrats to?PI Dr. Odayme Quesada, Susan Reilly, Emma Reis, David Niehaus, Trent Rissover,?and the rest of the MICRO2 study team at The Christ Hospital Health Network on scheduling their first patient in the MICRO2 trial! Currently serving as the Medical Director of the Women's Heart Center at The Christ Hospital Health Network, Dr. Odayme Quesada returns to MICRO2 after making significant contributions in the MICRO trial, the pilot study prior to MICRO2 which was the first in history to explore MCG's role in diagnosing coronary microvascular dysfunction (CMD). On the results from MICRO, Dr. Quesada commented, "This pilot data demonstrated MCG's ability to detect CMD in patients with ANOCA [angina with non-obstructive coronary arteries] using a 90-second non-invasive scan.... If this early data is accurate, MCG holds tremendous potential for the diagnosis of CMD in patients with ANOCA." The ongoing MICRO2 trial was designed and powered to validate the results from MICRO. Our team couldn't be happier to partner with?Dr. Quesada?and the rest of her team in working to make the diagnosis of CMD a simple, fast, and accessible process! #MICRO2 #CardioFluxMCG #microvascular #CMD #myocardialischemia #INOCA

ICYMI: Recently Willa Bluestone and Eddie Pauline, MBA, OhioCED hosted Representative Adam Mathews at the CardioFlux Imaging Institute with Genetesis. They were able to experience the ease and comfortability of CardioFlux Imaging. They received a full cardio scan and report in under 3 minutes! Huge thanks to our amazing Ohio Life Sciences companies like Genetesis for developing life-changing technology. We are grateful for our elected officials who are supporting innovation! #OhioLifeSciences #innovation #advocacy ?

In about 3 minutes, I had a full cardio scan and report in hand...amazing and disruptive life science technology...grateful for our elected officials like Rep.?Adam Mathews ?who are curious to learn more about the life-changing products that?Ohio Life Sciences companies like?Genetesis?are developing all over this state! Amazing work Peeyush Shrivastava Ryan Yoo ??Vineet Erasala Manny Setegn